Introduction {#S0001}
============

The prevalence of diabetes mellitus continues to increase worldwide. The International Diabetes Federation estimated that this number will reach 438 million by 2045.[@CIT0001] Abnormalities of corneal epithelium, corneal nerves, tear film, or corneal endothelium are observed in 70% of patients with diabetes.[@CIT0002],[@CIT0003] In general, these symptoms are described as diabetic keratopathy. Diabetic keratopathy includes increased corneal thickness, superficial punctate keratitis, delayed and incomplete wound repair, decreased endothelial cell density, and neuropathy resulting from reduced corneal sensitivity.[@CIT0004]--[@CIT0008] In addition, tear secretions in people with diabetes are lower than secretions in healthy individuals,[@CIT0009],[@CIT0010] with further worsening of corneal pathology in diabetic individuals exhibiting tear film instability as a result of reduced mucin secretion by conjunctival goblet cells.[@CIT0011],[@CIT0012] Several current treatments that use anti-inflammatory drugs for dry eye in diabetic patients have been reported.[@CIT0013] They reduce the signs, symptoms, and level of inflammation in dry eyes. However, effective drugs other than anti-inflammatory agents are desired because during treatment corneal epithelial defects are more common in diabetic patients than in dry eye patients without diabetes mellitus.

Diquafosol tetrasodium, a dinucleotide polyphosphate, is a purinoceptor agonist that binds to P2Y~2~ receptors on the ocular surface and stimulates both tear secretion and mucin secretion.[@CIT0014]--[@CIT0016] Diquafosol tetrasodium induces increased transepithelial fluid flow, with chloride ion secretion from the serosal to the mucosal side through the conjunctiva, along with enhanced mucin secretion from goblet cells and stimulated mucin gene expression in cornea epithelial cells.[@CIT0016]--[@CIT0019] Consequently, diquafosol tetrasodium protects the corneal epithelium from desiccation and improves the barrier function of the corneal epithelium by enhancing tear film stability.[@CIT0020] Recent clinical studies have also reported that 3% diquafosol tetrasodium ophthalmic solution (DQS) was effective in the treatment of general dry eye syndrome.[@CIT0021]--[@CIT0023] Because the effect of DQS on diabetic keratopathy has not been elucidated, this study was designed to evaluate the effects of instillation of DQS on tear volume, corneal sensitivity, and the progress of corneal epithelial damage under constant airflow exposure in diabetic model rats.

Materials and Methods {#S0002}
=====================

Animals {#S0002-S2001}
-------

Male 10-week-old Goto--Kakizaki (GK) rats and healthy male 10-week-old Wistar rats (which served as control animals) were obtained from Nihon SLC (Hamamatsu, Japan). The animals were allowed free access to laboratory chow and water, were quarantined and acclimatized for 1 week and kept with constant exposure to airflows (between 2 and 4 m/s to according to previous desiccation conditions[@CIT0024],[@CIT0025]) for 8 weeks to induce superficial punctate keratopathy. Twelve GK rats and six Wistar rats were used for measurement of blood glucose, corneal sensation, and tear secretion (Study 1). Eighteenth GK rats and nine Wistar rats were used for corneal fluorescein staining (Study 2). GK rats were then divided into two groups: saline instillation and DQS instillation groups. The study design is shown in [Figure 1](#F0001){ref-type="fig"}. The studies were performed in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the animal ethics committee of Santen Pharmaceutical Co., Ltd. (animal experimental ethics approval numbers: Study 1, DR130384; Study 2, DR130385).Figure 1Study design.**Abbreviation:** DQS, 3% diquafosol tetrasodium ophthalmic solution.

Instillation of Ophthalmic Solutions {#S0002-S2002}
------------------------------------

Five microliters of saline (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan) or 3% DQS (Santen Pharmaceutical Co., Ltd., Osaka, Japan) was instilled in the cornea of both the eyes of GK rats six times daily for 6 weeks. In contrast, Wistar rats received no instillation.

Measurement of Blood Glucose Level {#S0002-S2003}
----------------------------------

Glucose levels in blood drawn from a tail vein were measured using a Kantan Sokuto G checker (Sanko Junyaku Co., Ltd., Tokyo, Japan) before and after 6-week instillations.

Measurement of Corneal Sensation {#S0002-S2004}
--------------------------------

Corneal sensation of rats was measured with a Cochet--Bonnet esthesiometer (Handaya Co., Ltd., Tokyo, Japan). Initially, the nylon filament was fully extended to 60 mm. Objective blinking was considered a positive response. When no positive response was detected, the filament length became shortened, and the procedure was repeated until such a response was observed. When the response was obtained, the length of the nylon filament was measured as a parameter for corneal sensation before and after the 6-week instillation period.

Tear Secretion {#S0002-S2005}
--------------

We used a modified Schirmer's test on rats' eyes to measure tear fluid, with all animals under general anesthesia induced by sodium pentobarbital (Kyoritsu Seiyaku Corporation, Tokyo, Japan) before instillation and 15 mins after the last application of 6-week instillations. Schirmer strips (Showa Yakuhin Kako, Tokyo, Japan), cut to a length of 17 mm and a width of 1 mm, were inserted into the rat's lower eyelid for 1 min. Strip wetting length was measured to an accuracy of 0.5 mm.

Corneal Fluorescein Staining {#S0002-S2006}
----------------------------

For Study 2, saline or DQS was instilled six times daily for 6 weeks into the eyes of animals maintained under conditions of constant airflow. Damage to the corneal surface was observed with fluorescein staining using a slit lamp with a blue-free barrier filter (SL-8Z; Topcon Corporation., Tokyo, Japan), and corneal staining was graded as follows:[@CIT0026] corneas were geometrically divided into upper, center, and lower viewing areas. Each area of punctate staining was denoted as grade 0 when there was no staining, grade 1 when the staining was diffuse, grade 2 when the staining was intermediate between grade 1 and grade 3, and grade 3 when the staining was thick. For each area, a minimum score was set at 0.5, and scores were summed to obtain final scores. The maximum possible score was 9. The scorer was blinded to the type of treatment received by the rats. Corneal fluorescein staining was examined before instillation, and at 2-, 4-, and 6-week instillations.

Statistical Analysis {#S0002-S2007}
--------------------

Statistical analyses were performed using Student's *t*-test. All analyses were performed using EXSUS software, ver. 8.0.0 (SAS^®^ ver. 9.3) (CAC Exicare Co., Tokyo, Japan), and results were considered statistically significant if the *p* value was less than 0.05.

Results {#S0003}
=======

Clinical Characteristics of GK Rats {#S0003-S2001}
-----------------------------------

The blood glucose levels of GK/saline rats before and after instillation were significantly higher than those of control Wistar rats. No significant changes were observed in blood glucose levels between saline and DQS instillation in GK rat groups (229 ± 19 and 259 ± 28 mg/dL, respectively; [Table 1](#T0001){ref-type="table"}). Corneal sensation in GK/saline rats before and after instillation was significantly decreased compared with that in Wistar rats. No significant difference in corneal sensation was observed between saline and DQS treatments in GK rat groups (28 ± 1 and 31 ± 1 mm, respectively) ([Table 2](#T0002){ref-type="table"}).Table 1Effect of DQS on Blood Glucose of GK RatsWistar/noneGK/salineGK/DQSBlood Glucose (mg/dL)Before instillation103 ± 6\*\*204 ± 16230 ± 12After 6 weeks instillation102 ± 7\*\*229 ± 19259 ± 28[^1][^2] Table 2Effect of DQS on Corneal Sensation of GK RatsWistar/noneGK/salineGK/DQSMonofilament Length (mm)Before instillation59 ± 1\*\*25 ± 226 ± 2After 6 weeks instillation59 ± 1\*\*28 ± 131 ± 1[^3][^4]

Tear Secretion {#S0003-S2002}
--------------

[Figure 2](#F0002){ref-type="fig"} shows changes in Schirmer's test for control (Wistar rats, without instillation treatment), saline, and DQS instillation (GK rats) groups before and after instillation. Schirmer's test scores in GK rats was significantly lower than that of Wistar rats (*p* \< 0.01, Student's *t*-test), whereas no significant difference was found between saline and DQS groups before instillation. Schirmer's test scores did not change after instillation of saline for 6 weeks. In contrast, DQS significantly increased mean Schirmer's test scores compared with saline alone, based on the measurements taken 15 mins after the last application of the 6-week instillations (*p* \< 0.01, Student's *t*-test).Figure 2Effect of DQS on tear fluid secretion in diabetic GK rats exposed to airflow for 8 weeks. GK rats underwent instillation with saline or DQS six times daily for 6 weeks. Each measurement was obtained before and after the instillation period. Each column represents mean ± SE (n = 12 eyes). \*\**p* \< 0.01 vs GK/saline at the same time point (Student's *t*-test).**Abbreviations:** DQS, 3% diquafosol tetrasodium ophthalmic solution; N.S., not significant; GK, Goto--Kakizaki, SE, standard error.

Corneal Fluorescein Staining {#S0003-S2003}
----------------------------

[Figure 3A](#F0003){ref-type="fig"} shows rat corneas stained with fluorescein sodium solution. Wistar rat corneas showed sparse and localized staining, GK/saline group corneas were stained heavily. Applications of DQS six times daily for 6 weeks to GK group corneas reduced corneal fluorescein staining (GK/DQS) compared to that observed with saline application. Mean corneal fluorescein staining scores for GK/saline rats were significantly higher than scores recorded in Wistar rats at all measurement points (*p* \< 0.01). As with other tests performed, no statistically significant differences were observed between saline and DQS instillation groups (GK rats) with respect to this parameter before instillation commenced. DQS significantly decreased corneal fluorescein staining compared with saline 4 and 6 weeks after instillation (4 weeks, *p* \< 0.05; 6 weeks, *p* \< 0.01) ([Figure 3B](#F0003){ref-type="fig"}).Figure 3Effect of DQS on corneal fluorescein staining score in diabetic rats exposed to constant airflow. Male GK rats were maintained with constant airflow while subjected to instilled saline or DQS for 6 weeks. The corneal staining score was determined before instillation and at 2-, 4-, and 6-week instillations. (**A**) Representative images of the corneal epithelium with fluorescein staining in rats at 6-week instillation. Wistar rat served as control. (**B**) Time course of corneal fluorescein staining score. Each point represents the mean ± SE (n = 18 eyes). \**p* \< 0.05, \*\**p* \< 0.01 vs GK/saline (Student's *t*-test). ^\#\#^*p* \< 0.01 vs Wistar (Student's *t*-test).**Abbreviations:** DQS, 3% diquafosol tetrasodium ophthalmic solution; GK, Goto--Kakizaki, SE, standard error

Discussion {#S0004}
==========

We investigated the effects of DQS on tear secretion, corneal fluorescein staining, and corneal sensation in diabetic GK rats. The GK rat is a spontaneous model of type 2 diabetes Wistar rats with glucose intolerance, characterized by mild hyperglycemia.[@CIT0027],[@CIT0028] In terms of ocular surfaces, GK rats exhibit decreased tear secretion, lower corneal sensation, and corneal epithelial wound healing rate delay,[@CIT0029] whereas all these signs have not been reported in Otsuka Long-Evans Tokushima Fatty rats, another spontaneous model of type 2 diabetes.[@CIT0030] Among patients with diabetes, the following conditions are observed: decreased tear secretion,[@CIT0009],[@CIT0010] lower corneal sensation,[@CIT0009] corneal epithelial wound healing delay,[@CIT0008] shortened tear film breakup time (BUT),[@CIT0010],[@CIT0011] and decreased goblet cell density.[@CIT0011] Tear secretion, especially reflex tear secretion, is regulated by the peripheral sensory system.[@CIT0031] Given that corneal sensation is decreased in diabetic patients, attenuated tear secretion might have been caused by reduced stimulation from the corneal surface. Moreover, although the mechanisms of loss of goblet cell density remain unclear, it is possible that a decrease in the trophic effects of trigeminal sensory nerves on the conjunctiva and cornea may be responsible. Decreased mucin by loss of goblet cell may cause shortened BUT. The tear film abnormality due to decreased tear quality and quantity may induce corneal epithelial damage in diabetic patients. GK rats and diabetic patients exhibit several common signs on the ocular surface. However, despite decreased tear volume in these animals, we did not observe corneal epithelial damage in GK rats that mimicked what is seen in patients with moderate or severe dry eye. In general, exposure to airflow raises the evaporation rate of tear fluid.[@CIT0032] This increased evaporation of tear film is one risk factor for dry eye. Airflow is used for dry eye animal models to evaporate the tear film.[@CIT0024],[@CIT0025] In this study, airflow was used, and diabetic GK rats housed with constant airflow exhibited superficial punctate keratopathy in the corneal epithelium as well, mimicking dry eye in patients with diabetes.

DQS increases tear secretion from the ocular surface in dry eye, thereby improving superficial punctate keratopathy.[@CIT0021]--[@CIT0023] In this study, DQS increased Schirmer's test scores but did not influence corneal sensitivity and blood sugar levels in diabetic rats. Based on these results, DQS is thought to increase tear secretion from the ocular surface in diabetic rats without reflex tear secretion via the peripheral sensory system of cornea and conjunctiva or improvement of blood sugar levels. Moreover, DQS decreased corneal fluorescein staining scores in diabetic rats in this study. DQS is reported to promote not only tear secretion but also mucin secretion.[@CIT0033] Because DQS increased both of these secretions might be attributable to the increase in tear stability in terms of tear quality and tear quantity, resulting in improvement of corneal epithelial damage. In this study, mucin secretion increase by DQS was not measured; however, an increase in mucin secretion could underlie the observed improvement in corneal epithelial damage. The mechanism of action of DQS on diabetic rats with dry eye should be elucidated in future studies.

We demonstrated in this study that DQS increases tear secretion and improves superficial punctate keratopathy in diabetic GK rats. DQS, an ophthalmic solution for dry eye different from anti-inflammatory drugs, may have potential for the treatment of abnormalities of tear film and of ocular surface damage in diabetic patients with dry eye.
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[^1]: **Notes:** Mean ± SE. \*\**p* \< 0.01 vs GK/saline (Student's *t*-test). No significant difference was found between GK/saline and GK/DQS rats (Student's *t*-test).

[^2]: **Abbreviations:** DQS, diquafosol tetrasodium 3% ophthalmic solution; GK, Goto--Kakizaki; SE, standard error.

[^3]: **Notes:** Mean ± SE. \*\**p* \< 0.01 vs GK/saline (Student's *t*-test). No significant difference was observed between GK/saline and GK/DQS rats (Student's *t*-test).

[^4]: **Abbreviations:** DQS, diquafosol tetrasodium 3% ophthalmic solution; GK, Goto--Kakizaki; SE, standard error.
